Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality.
JACC Heart Fail
; 11(7): 810-821, 2023 07.
Article
en En
| MEDLINE
| ID: mdl-37115134
ABSTRACT
BACKGROUND:
Over the past years, it has become clear that the microbial ecosystem in the gut has a profound capacity to interact with the host through the production of a wide range of bioactive metabolites. The microbially produced metabolite imidazole propionate (ImP) is clinically and mechanistically linked with insulin resistance and type 2 diabetes, but it is unclear how ImP is associated with heart failure.OBJECTIVES:
The authors aimed to explore whether ImP is associated with heart failure and mortality.METHODS:
ImP serum measurements in 2 large and independent clinical cohorts of patients (European [n = 1,985] and North American [n = 2,155]) with a range of severity of cardiovascular disease including heart failure. Univariate and multivariate Cox regression analyses were performed to delineate the impact of ImP on 5-year mortality in the North American cohort, independent of other covariates.RESULTS:
ImP is independently associated with reduced ejection fraction and heart failure in both cohorts, even after adjusting for traditional risk factors. Elevated ImP was a significant independent predictor of 5-year mortality (for the highest quartile, adjusted HR 1.85 [95% CI 1.20-2.88]; P < 0.01).CONCLUSIONS:
The gut microbial metabolite ImP is increased in individuals with heart failure and is a predictor of overall survival.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus Tipo 2
/
Insuficiencia Cardíaca
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
JACC Heart Fail
Año:
2023
Tipo del documento:
Article
País de afiliación:
Suecia